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A simple and convenient method for the synthesis of biologically active sulfonamide derivatives of p-nitrobenzene 
sulfonylchloride has been achieved. All the title compounds have been characterized by spectral and elemental analysis. 
They have been further screened in vitro for their antibacterial and antifungal activities. All the compounds show good to 
moderate activity against both bacteria and fungi when compared with standard bactericide, Streptomycin and fungicide, 
Nystatin. 
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The treatment of bacterial infections remains a 
therapeutic challenge because of emerging infectious 
diseases and the increasing number of multidrug-
resistant microbial pathogens. Inspite of the many 
antibiotics and chemotherapeutics available, the 
emergence of old and new antibiotic-resistant bacterial 
strains in the last two decades has led to a substantial 
need for new classes of anti-microbial agents. 
The discovery of sulfonamides as antibacterials in 
the early 1930s was the beginning of the most 
fascinating era of chemotherapeutic agents1-4. Since 
the introduction of prontosil over 70 years ago, sulfa 
drugs have been widely used to treat a broad spectrum 
of microbial diseases5. 
However, due to the rapid emergence of 
sulfonamide resistant organisms and the development 
of more potent drugs have limited their clinical  
use. Sulfonamide derivatives exhibit various types  
of pharmacological activities such as antibacterial6, 
antiprotozoal7, antifungal8, antiinflammatory9, 
nonpeptidic vasopressin receptor antagonists10 and 
translation initiation inhibitors11. Some important 
sulfonamide derivatives have been used as carbonic 
anhydrase inhibitors of commercial importance12. They 
are also effective for the treatment of urinary, intestine, 
and ophthalmic infections, scalds, ulcerative colitis13, 
rheumatoid arthritis14, male erectile dysfunction as the 
phosphodiesterase-5 inhibitor sildenafil – better known 
under its commercial name, Viagra15, and obesity16. 
More recently, sulfonamides are being used as 
anticancer agents17, as the antiviral HIV protease 
inhibitor amprenavir18 and in Alzheimer’s disease19. 
Some organisms are resistant to all approved 
antibiotics and can only be treated with experimental 
and potentially toxic drugs. Therefore, there is an 
overwhelming need to develop more effective 
antibacterial agents to treat infections caused by 
antibiotic resistant bacterial pathogens. Sulfonamides 
exert their effect by targeting on dihydropteroate 
synthase (DHPS) enzyme, which catalyzes folic acid 
pathway in bacteria and some eukaryotic cells20 but is 
not present in human cells21. This is the basis for the 
selective effect of sulfonamides on bacteria and for 
their broad spectrum of antibacterial activity. 
Due to the broad applicability of sulfonamides, it is 
desirable to find general and effective methods for 
their synthesis. Thus synthesis of these compounds is 
of continuing interest. To date many synthetic 
methods have been reported. Motivated by the afore-
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mentioned literature and in persistence of our earlier 
work on different sulfonamide derivatives22, we 
envision our approach towards the design and 
synthesis of structurally diverse series of sulfonamide 
derivatives for their antimicrobial activity. 
 
Results and Discussion 
Chemistry 
The synthesis of sulfonamide derivatives 3a-j was 
performed by reaction between p-nitrobenzene 
sulfonyl chloride 1 and various primary 2a-f, 
secondary 2g-j bioactive amines in the presence of 
triethylamine as a base with high yields in short 
reaction time. The synthetic protocol for the title 
compounds was presented in Scheme I. 
The chemical structures of all the title compounds 
3a-f were characterized by spectral data (1H, 13C, IR 
and LC-MS), elemental analyses and the results were 
presented in experimental section. The structure of 3a 
is interpreted from spectroscopic data. IR spectra of 
compound 3a reveals absorption band in the region 
3448 cm−1 corresponding to -NH stretching vibrations 
in indole ring. The absorption band in the region 3382 
cm−1 corresponding to aliphatic-NH stretching 
vibrations for the compound 3a. Two absorption 
bands at 1318, 1173 cm−1corresponds to SO2 
stretchingvibrations. The absorption at 934 cm−1 is 
due to S–N stretching vibrations. In the 1H NMR 
spectra of 3a, displayed multiplets in the region δ 
7.60-7.11 due to aromatic protons. The indolic-NH 
proton was highly deshielded and appeared at δ 10.1. 
IR spectra of compound 3i gave absorption band 
the absorption bands at 1346, 1169 cm−1 were due to 
SO2 stretching vibrations. The band at 887 cm−1was 
due to S–N stretching. In 1H NMR spectra of 3i, 
aromatic protons resonated in the range δ 8.42-6.79 as 
doublets. The triplet at δ 3.22 was due to proton in 
piperazine moiety. 
In 13C NMR spectra, chemical shifts for the title 
compounds were observed in the expected regions. In 
their mass spectra, M+.ions were observed in the 
expected m/z values. 
 
Biological activity 
Molecular docking analysis 
In order to provide strength to the synthesized 
compounds, docking analysis was carried out for 
compounds 3a-j with selective pharmacological target 
such as DNA Gyrase A protein (Figure 1, A) of E. 
coli which is a suitable target for anti-bacterial 
activity. The crystal structure of DNA Gyrase A (PDB 
id: 3LPX) was retrieved from the protein data bank, 
and the reference drug Streptomycin Figure 1, B) (PC 
ID 19649) Pub Chem Drug bank.The docking results 
of DNA Gyrase A showed that compounds 3j, 3h, 3f, 
3i and 3a have significant binding modes, with dock 
scores (Table I) of -8.2, -8.1, -7.7, -7.5 and -7.2 k 
cal/mol when compared with the control drug 
Streptomycin (-6.9) respectively. The H-bonds, 
binding affinities and energy profiles of compounds 
3a-j along with reference drug, towards the active site 
amino acids of the enzyme are summarized in Table I. 
The binding modes of compounds 3j, 3h, 3f, 3i and 
3a suggested that they fitted more stably into the 
DNA Gyrase A binding pocket. Hence, the present 
investigation demonstrate that the synthesised 
compounds will be the promising next generation 
anti-microbial drugs, which can be effectively used in 
the treatment of microbial and other related 
infections.  
 
Antibacterial activity 
The title compounds 3a-j were screened for 
antibacterial activityat two different concentrations, 
100 and 200 µg/mL, against two Gram positive  
(B. subtilis, S. aureus) and two Gram negative bacteria 
(E. coli, P. aeruginosa) using disc diffusion method. 
The bactericide, Streptomycin was used as a standard 
to compare the activity of the title compounds. The 
results revealed that all the title compounds exhibited 
moderate to good activity against both Gram-positive 
and Gram-negative bacteria (Table II). 
Especially the compounds 3j bearing 4-
fluorophenyl piperazine moiety, 3h incorporated with 
4-nitrophenyl piperazine moiety, 3f having 1,3-
dimethyl-2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl 
moiety, 3i bearing 4-chlorophenyl piperazine moiety, 
3a linked withindole moiety; exhibited good activity 
against both Gram-positive and Gram-negative 
bacteria. The remaining compounds displayed 
moderate activity against Gram-positive bacteria and 
Gram negative bacteria. 
 
Antifungal activity 
The title compounds were also evaluated for their 
antifungal activityat two different concentrations, 150 
and 250 µg/mL, against four fungi, Aspergillus niger, 
Aspergillus flavus, Penicilliumnotatum and Fusarium 
solani. The fungicide Nystatin was used as a standard 
to compare the activity of the title compounds. The  
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Figure 1 — Docking structures of the compounds 
 
observed results on the antifungal activity of the title 
compounds and control drug are given in Table III. 
Especially the compounds 3g bearing propanoate 
moiety, 3j linked with 4-fluorophenyl piperazine 
moiety, 3b incorporated with pentanoate moiety, 3d 
having 3,4-dihydroxyphenethyl moiety and3i bearing 
4-chlorophenyl piperazine moiety exhibited good 
activity against fungi when compared with the 
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standard fungicide, Nystatin. All the remaining 
compounds showed moderate activity. 
 
Biological assay 
Molecular docking analysis 
Molecular docking studies23,24were carried against 
DNA Gyrase A protein with compounds 3a-j, and the  
 
reference drug Streptomycin (A), using the docking 
module implemented in Pyrx 2010.12. Initially the 
protein structures were protonated with the addition of 
polar hydrogens, followed by energy minimization 
with the MMFF94x force field, in order to get the 
stable conformer of the protein. Flexible docking was 
Table I — Bonding characterization of synthesized compounds 3a-j and STM (A), Reference drug) against E. coli DNA Gyrase A protein
S. No. Compd Rank Binding energy 
(K cal mol−1) 
Binding interaction Bond Length(Å) Bond Angle (°) Bond Type 
A Streptomycin 
 
R −6.9 Arg 139 CG…HN 
Leu 135 CD…HN 
His 132 CB…OH 
Asp 53 CG…OC 
Asp 53 OC…OC 
Asp 58 OD…OH 
Asp 58 OD…HN 
His 132 ND…OC 
His 132 ND…OC 
His 132 OC…OH 
2.2 
2.7 
2.5 
3.4 
2.9 
2.0 
2.5 
2.8 
2.7 
2.5 
124.4 
125.7 
125.0 
116.7 
118.9 
118.6 
116.4 
126.2 
120.0 
119.8 
H- don 
H- don 
H- acc 
H- acc 
H- acc 
H- acc 
H- don 
H- acc 
H- acc 
H- acc 
1 3a 5.0 −7.2 Asp 297 CA ….HN 
Val 112 CA ….OS 
Lys 270 NZ ….OC 
2.6 
2.3 
2.1 
112.4 
114.3 
110.3 
H- don 
H- acc 
H- acc 
2 3b 9.0 −5.9 Lys 270 NC ….OC 2.4 124.6 H- acc 
3 3d 7.0 −6.3 Asp 297 CA ….HN 
Leu 264 CA …..ON 
2.4 
2.2 
122.4 
114.7 
H- don 
H- acc 
4 3e 8 −6.1 Asp 297 CB ….HN 
Val 112 CB ….OC 
2.6 
2.2 
122.2 
73.6 
H- don 
H- acc 
5 3f 3 −7.7 Gln 94 CG …..OC 
Gln 94 CG …..OC 
Arg 91 CZ …..OS 
Thr 219 CB ….ON 
3.2 
2.4 
2.2 
2.3 
99.6 
65.6 
119.0 
109.6 
H- acc 
H- acc 
H- acc 
H- acc 
6 3g 6 −6.5 Asp 297 CA ….HN 
Lys 270 NZ …..OC 
2.0 
2.3 
122.4 
110.3 
H- don 
H- acc 
7 3h 2 −8.1 Ala 117 CA …..ON 
Met 301 CA ….ON 
2.1 
2.3 
114.9 
115.2 
H- acc 
H- acc 
8 3i 4 −7.5 Leu 264 NN …..ON 2.1 90.6 H- acc 
9 3j 1 −8.2 Thr 219 CB …..ON 
Thr 219 CB …..ON 
Gln 267 CB …..ON 
2.3 
2.3 
1.9 
109.6 
109.6 
129.4 
H- acc 
H- acc 
H- acc 
 
Table II — Antibacterial activity of the title compounds 3a-j 
Compd Zone of Inhibition in mm 
Bacillus subtilis  Pseudomonas aeruginosa  Staphylococcus aureus  Escherichia coli 
150 µg/mL 250 µg/mL  150 µg/mL 250 µg/mL  150 µg/mL 250 µg/mL  150 µg/mL 250 µg/mL 
3a 9 13  11 13  18 20  15 18 
3b 8 10  8 10  11 14  11 14 
3c 0 0  9 13  9 12  10 13 
3d 8 11  11 14  14 17  9 13 
3e 8 11  15 17  11 13  18 21 
3f 10 13  9 12  8 11  15 18 
3g 0 9  12 15  10 12  8 10 
3h 12 14  10 13  18 21  16 19 
3i 10 13  9 13  09 12  12 15 
3j 12 15  12 15  11 14  14 17 
Std 14 16  12 15  13 15  16 20 
Std: Streptomycin 
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employed, the inhibitor binding site residues were 
softened and highlighted through the “Site Finder” 
module implemented in the Pymol software. The grid 
dimensions were predicted as ˚ X: 28.27, Y: 27.13, Z: 
28.51 for DNA Gyrase Arespectively. The docking 
was carried out with the default parameters i.e., 
placement: triangle matcher, recording 1: London dG, 
refinement: force field, and a maximum of 10 
conformations of each compound were allowed to be 
saved in a separate database file in a. mdb format. 
After the docking process, the binding energy  
and binding affinity of the protein-ligand complexes 
were calculated using Pymol viewer tool 
(www.pymol.org).25 
 
Antibacterial activity 
All the newly synthesized compounds were 
screened for their antibacterial activity against Gram 
positive bacteria, Bacillus subtilis (MTCC- 441), 
Staphylococcus aureus (MTCC-737) and Gram 
negative bacteria, Escherichia coli (MTCC- 443), 
Pseudomonas aeruginosa (MTCC-741) using a disk 
diffusion method. 2 mg of the title compounds and the 
standard drug were dissolved in 10 mL of 
dimethylsulphoxide (DMSO) and further diluted to a 
concentration of 100 and 200 µg /mL of the tested 
samples. The sterile nutrient agar medium was pored 
into a set of petri plates and allowed few minutes for 
solidification after 20 µL of respective bacterial 
culture was uniformly spread on the surface of the 
nutrient agar medium with sterile inocula or ‘L’ shape 
glass rod. The sterile disks (6 mm diameter) 
previously soaked in 150 and 250 µg/mL test 
solutions were placed on petri plates and incubated 
for 24 h at 37±1°C. The zone of inhibition around the 
disc was measured. Streptomycin was used as a 
positive control and DMSO was used as a negative 
control. For each treatment, triplicate experiments 
were carried out and the average zone of inhibition 
was calculated in mm (Table II). 
 
Antifungal activity 
Antifungal activity of the synthesized compounds 
was screened against Aspergillus niger, Aspergillus 
flavus,Penicilliumnotatumand Fusarium solani by the 
poison food technique. 2 mg of the synthesized and of 
the standard (Nystatin) compounds were dissolved in 
10 mL of dimethylsulphoxide (DMSO) and their 
concentrations were adjusted to 150 and 250 µg/mL 
by dilution before mixing with potato dextrose agar 
medium (PDA). 5 mm of mycelia disc was cut from 
the respected culture medium with a sterilized cork 
borer, inoculated in the center of the PDA plate and 
incubated for 5 days at 26±2°C. Nystatin was used as 
a positive control while a disk dipped in DMSO was 
used as a negative control. Triplicate experiments 
were carried out for each treatment and results were 
expressed in mm (Table II). The inhibiting activity of 
the title compounds was calculated by the formula 
I=C-T/C, where ‘I’ indicates the rate of inhibition, ‘C’ 
indicates the diameter of fungi growth in the control 
and ‘T’ indicates the diameter of fungi growth in 
treatment.  
Table III — Antifungal activity of the title compounds 3a-j 
Compd Percent Inhibition of Fungal growth 
Aspergillus niger  Aspergillus flavus  Penicilliumnotatum  Fusarium solani 
150 µg/mL 250 µg/mL  150 µg/mL 250 µg/mL  150 µg/mL 250 µg/mL  150 µg/mL 250 µg/mL 
3a 53 67  59 65  58 65  55 69 
3b 66 75  67 78  67 79  67 73 
3c 54 66  56 69  56 65  59 67 
3d 66 72  65 72  65 70  68 73 
3e 55 68  54 66  57 67  59 68 
3f 42 60  43 55  45 60  46 59 
3g 75 80  72 80  66 82  70 82 
3h 62 75  65 76  60 78  62 72 
3i 65 76  62 73  65 75  64 78 
3j 69 70  69 75  69 77  63 73 
Blank 
(DMSO) 
00 00  00 00  00 00  00 00 
Std 60 75  65 75  62 76  60 75 
Std: Nystatin 
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Experimental Section 
Chemicals were purchased from Sigma-Aldrich, 
Merck and Lancaster, and were used as received 
without further purification. All solvents used for 
spectroscopic and other physical studies were of 
reagent grade and were further purified by literature 
methods. Melting points were determined using a 
calibrated thermometer by Guna Digital Melting Point 
apparatus. IR spectra were recorded as KBr discs on a 
Nicolet 380 FT-IR spectrophotometer. 1H and 
13C NMR spectra were recorded as solutions in 
DMSO-d6 on a Bruker AMX 500 MHz spectrometer 
operating at 500 MHz for 1H and 500 MHz for 13C. 
The 1H and 13C chemical shifts were referenced to 
tetramethylsilane. Electrospray ionization mass 
spectrometry (ESI-MS) was performed on a Bruker 
electrospray mass spectrometer. Elemental analyses 
were performed on a ThermoFinnigan Instrument at 
University of Hyderabad, Hyderabad, India. 
 
General procedure for the synthesis of title 
compounds, 3a-j 
To a stirred solution of methyl 2-amino-3-(1H-
indol-3-yl) propanoate 2a (1 mmol) in dry THF, p-
nitrobenzene sulfonyl chloride 1 (1 mmol) was added 
at 0°C in the presence of triethylamine (1.2 mmol) as 
a base in THF (20 mL). After the addition, the 
reaction mixture temperature was slowly raised to  
40-45°C and stirred for 4 h. The progress of the 
reaction was monitored by TLC using ethyl acetate: 
hexane (3:2). After completion of the reaction, the 
triethylamine hydrochloride salt was filtered off and 
the solvent was removed in a rotary evaporator. The 
residue was purified by washing with hexane and 
recrystallization from ethanol. The resulting 
compound Methyl 3-(1H-indol-3-yl)-2-(4-nitrophenyl- 
sulfonamido)propanoate 3a was obtained in good 
yield (86%). The same procedure was adopted for the 
synthesis of the remaining title compounds 3b-j 
(Scheme I). 
 
Spectral data of title compounds, 3a-j 
Methyl 3-(1H-indol-3-yl)-2-(4-nitrophenyl-sulfo-
namido)propanoate, 3a: Yield 86%. m.p.173-174°C. 
1H NMR (500 MHz, CDCl3): δ 10.1 (s, 1H, Indololic-
NH), 8.42 (d, 2H, J = 8.5 Hz, Ar-H), 7.99 (d, 2H, J = 
8.5 Hz, Ar-H), 7.74 (s, 1H, NH), 7.60-7.11 (m, 5H, 
Ar-H), 3.81 (t, 1H, J = 6.0 Hz, -CH-COO), 3.68 (s, 
3H, -OCH3), 3.42 (m, 1H, -CH2-), 3.17 (m, 1H, -CH2-); 
13C NMR (500 MHz, CDCl3): δ 171.5, 151.1, 150.6, 
136.5, 128.2, 127.4, 124.2, 123.0, 121.7, 119.8, 118.8, 
111.1, 109.7, 59.5, 51.9, 29.6; IR (KBr): 3448 
O2N S
O
O
Cl + Et3N, THF
10-50°
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Scheme I — Synthesis of sulfonamide derivatives of p-nitrobenzene sulfonyl chloride 
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(Indole-NH), 3382 (NH), 1318, 1173 (SO2 str.), 934 
cm−1 (S-N str,); EI-MS: m/z 403. Anal. Calcd for 
C18H17N3O6S: C, 53.59; H, 4.25; N, 10.42. Found: C, 
53.54; H, 4.20; N, 10.37%. 
 
(S)-Methyl 4-methyl-2-(4-nitrophenyl-sulfonamido) 
pentanoate, 3b: Yield 90%. m.p.130-132°C. 
1H NMR (500 MHz, CDCl3): δ 8.42 (d, 2H, J = 8.5 
Hz, Ar-H), 7.99 (d, 2H, J = 8.5 Hz, Ar-H), 7.74 (s, 
1H, NH), 3.68 (s, 3H, -OCH3), 3.45 (m, 1H, SO2NH-
CH-), 1.87 (t, 2H, J = 6.1 Hz, -CH2-), 1.49 (m, 1H, -
CH(CH3)2) 0.91 (d, 6H, J = 7.6 Hz, -CH(CH3)2); 
13C NMR (500 MHz, CDCl3): δ 171.5, 151.1, 150.6, 
128.2, 124.2, 53.5, 51.9, 39.7, 24.8, 22.9; IR (KBr): 
3285 (NH), 1723 (C=O), 1320, 1174 (SO2 str.), 911 
cm−1 (S-N Str); EI-MS: m/z 330. Anal. Calcd for 
C13H18N2O6S: C, 47.26; H, 5.49; N, 8.48. Found: C, 
47.21; H, 5.45; N, 8.44%. 
 
N-(2-(1H-Indol-3-yl)ethyl)-4-nitrobenzene-sulfo-
namide, 3c: Yield 89%. m.p.162-163 ͦC. 1H NMR 
(500 MHz, CDCl3): δ 10.1 (s, 1H, Indololic-NH), 8.42 
(d, 2H, J = 8.5 Hz, Ar-H), 7.99 (d, 2H, J = 8.5 Hz, Ar-
H), 7.74 (s, 1H, NH), 7.60-7.11 (m, 5H, Ar-H), 3.43 
(t, 2H, methylene-H), 2.71 (t, 2H, J = 6.8 Hz, 
methylene-H); 13C NMR (500 MHz, CDCl3): δ 151.1, 
150.6, 136.5, 128.2, 127.4, 124.2, 123.0, 121.7, 119.8, 
118.8, 113.0, 111.1, 43.9, 27.9; IR (KBr): 3443 
(Indole-NH), 3380 (NH), 1315, 1175 (SO2 str.), 938 
cm−1 (S-N str,); EI-MS: m/z 345). Anal. Calcd for 
C16H15N3O4S: C, 55.64; H, 4.38; N, 12.17. Found: C, 
55.60; H, 4.34; N, 12.12%. 
 
N-(3,4-Dihydroxyphenethyl)-4-nitrobenzene-sulfo-
namide, 3d: Yield 83%. m.p.142-144°C. 1H NMR 
(500 MHz, CDCl3): δ 9.48 (s, 2H, Ar-OH), 8.42 (d, 
2H, J = 8.5 Hz, Ar-H), 7.99 (d, 2H, J = 8.5 Hz, Ar-H), 
7.74 (s, 1H, NH), 6.86-6.68 (m, 3H, Ar-H), 5.35 
(1H,OH), 3.49 (t, 2H, J = 6.8 Hz, methylene-H), 
2.83(t, 2H, J = 7.2 Hz, methylene-H); 13C NMR (500 
MHz, CDCl3): δ 151.1, 150.6, 145.6, 144.5, 131.5, 
128.2, 124.2, 122.8, 116.4, 115.9, 42.8, 34.5; IR 
(KBr): 3399 (Phenolic-OH), 3222 (-NH), 1314, 1176 
(SO2 str.), 919 cm−1 (S-N Stretch); EI-MS: m/z 338. 
Anal. Calcd for C14H14N2O6S: C, 49.70; H, 4.17; N, 
8.28. Found: C, 49.65; H, 4.13; N, 8.24%. 
 
(R)-Methyl 3-methyl-2-(4-nitrophenyl-sulfo-
namido) butanoate, 3e: Yield 82%. m.p.122-124°C. 
1H NMR (500 MHz, CDCl3): δ 8.42 (d, 2H, J = 8.5 
Hz, Ar-H), 7.99 (d, 2H, J = 8.5 Hz, Ar-H), 7.74 (s, 
1H, NH), 3.68 (s, 3H, -OCH3), 3.44 (m, 1H, NH-CH-
), 2.67 (m, 1H, -CH(CH3)2), 0.91 (d, 6H, J= 7.2 Hz, -
CH(CH3)2); 13C NMR (500 MHz, CDCl3): δ 171.5, 
151.1, 150.6, 128.2, 124.2, 63.1, 51.9, 29.6, 18.9; IR 
(KBr): 3334 (NH), 1721 (C=O), 1298, 1164 (SO2str), 
907 cm−1 (S-N Stretch); EI-MS: m/z 316. Anal. Calcd 
for C12H16N2O6S: C, 45.56; H, 5.10; N, 8.86. Found: 
C, 45.51; H, 5.05; N, 8.82%. 
 
N-(1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-
pyrimidin-4-yl)-4-nitrobenzenesulfonamide, 3f: 
Yield 75%. m.p.132-133˚C. 1H NMR (500 MHz, 
CDCl3): δ 8.42 (d, 2H, J = 8.5 Hz, Ar-H), 7.99 (d, 2H, 
J = 8.5 Hz, Ar-H), 4.50(s, 1H, Pyrimidine-H), 3.16 (s, 
3H, -N-CH3), 3.01 (s, 3H, -N-CH3), 2.0 (s, 1H, 
SO2NH); 13C NMR (500 MHz, CDCl3): δ 163.2, 
162.3, 151.4, 151.1, 146.9, 128.2, 124.2, 75.5, 30.1, 
29.4; IR (KBr): 3385 (NH), 1754 (C=O), 1310, 1166 
(SO2 str.), 912 cm−1 (S-N Stretch); EI-MS: m/z 340. 
Anal. Calcd for C12H12N4O6S: C, 42.35; H, 3.55; N, 
16.46. Found: C, 42.31; H, 3.51; N, 16.41%. 
 
Methyl 2-(4-nitrophenylsulfonamido)-3-phenyl-
propanoate, 3g: Yield 77%. m.p.145-147 Cͦ. 1H NMR 
(500 MHz, CDCl3): δ 8.42 (d, 2H, J = 8.5 Hz, Ar-H), 
7.12 (d, 2H, J = 7.9 Hz, Ar-H), 7.74 (s, 1H, NH), 
7.23-6.60 (m, 5H, Ar-H), 3.68 (s, 3H, -COO-CH3), 
3.63 (q, 1H, -CH-CH2), 1.41 (d, 2H, -CH-CH2); 
13C NMR (500 MHz, CDCl3): δ 171.5, 151.1, 144.7, 
138.8, 138.3, 129.5, 128.2, 124.2, 120.8, 62.1, 51.9, 
13.8; IR (KBr): 3389 (NH), 1725 (C=O), 1311, 1170 
(SO2 str.), 914 cm−1 (S-N Stretch); EI-MS: m/z 364. 
Anal. Calcd for C16H16N2O6S: C, 52.74; H, 4.43; N, 
7.69. Found: C, 52.71; H, 4.40; N, 7.65%. 
 
1-(4-Nitrophenyl)-4-((4-nitrophenyl)-sulfonyl) 
piperazine, 3h: Yield 79%. m.p.171 – 172°C. 
1H NMR (500 MHz, CDCl3): δ 8.42 (d, 2H, J = 8.5 
Hz, Ar-H), 7.99 (d, 2H, J = 8.5 Hz, Ar-H), 7.21 (d, 
2H, J = 8.5 Hz, Ar-H), 6.79 (d, 2H, J = 9.0 Hz, Ar-H), 
3.22 (t, 8H, J = 5.0 Hz, piperazine-H); 13C NMR (500 
MHz, CDCl3): δ 155.7, 151.1, 145.8, 137.4, 128.2, 
124.8, 124.2, 112.3, 53.1, 48.4; IR (KBr): 1510, 1325 
(NO2 Str.), 1315, 1168 (SO2 str.), 918 cm−1 (S-N 
Stretch); EI-MS: m/z 392. Anal. Calcd for 
C16H16N4O6S: C, 48.97; H, 4.11; N, 14.28. Found: C, 
48.93; H, 4.06; N, 14.24%. 
 
1-(4-Chlorophenyl)-4-((4-nitrophenyl)-sulfonyl) 
piperazine, 3i: Yield 88%. m.p.179-180°C. 1H NMR 
(500 MHz, CDCl3): δ 8.42 (d, 2H, J = 8.5 Hz, Ar-H), 
7.99 (d, 2H, J = 8.5 Hz, Ar-H), 7.21 (d, 2H, J = 8.5 
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Hz, Ar-H), 6.79 (d, 2H, J = 9.0 Hz, Ar-H), 3.22 (t, 
8H, J = 5.0 Hz, piperazine-H); 13C NMR (500 MHz, 
CDCl3): δ 150.3, 149.0, 141.6, 131.0, 129.1, 128.9, 
124.4, 118.2, 49.2, 45.8; IR (KBr): 1346, 1169 (SO2 
str.), 887 (S-N), 765 cm−1 (C-Cl); EI-MS (m/z, %): 
381 (M)+, 383 (M+2). Anal. Calcd for 
C16H16ClN3O4S: C, 50.33; H, 4.22; N, 11.00. Found: 
C, 50.29; H, 4.18; N, 10.95%. 
 
1-(4-Fluorophenyl)-4-((4-nitrophenyl)-sulfonyl) 
piperazine, 3j: Yield 70%. m.p.175-176°C. 1H NMR 
(500 MHz, CDCl3): δ 8.42 (d, 2H, J = 8.5 Hz, Ar-H), 
7.99 (d, 2H, J = 8.5 Hz, Ar-H), 7.06 (d, 2H, J = 7.9 
Hz, Ar-H), 6.74 (d, 2H, J = 8.9 Hz, Ar-H), 3.22 (t, 
8H, J = 5.0 Hz, piperazine-H); 13C NMR (500 MHz, 
CDCl3): δ 156.8, 151.1, 145.8, 145.2, 128.2, 124.2, 
116.4, 115.9, 53.1, 48.4; IR (KBr): 1343, 1177 (SO2 
str.), 1095 (C-F Str.), 917 cm−1 (S-N Str.); EI-MS: m/z 
365. Anal. Calcd for C16H16ClN3O4S: C, 52.59; H, 
4.41; N, 11.50. Found: C, 52.54; H, 4.37; N, 11.45%. 
 
Conclusion 
A simple and convenient method was developed 
for the synthesis of a series of new sulfonamide 
derivatives of p-nitrobenzene sulfonyl chloride  
with high yields by reacting p-nitrobenzene 
sulfonylchloride with various biologically active 
amines. These compounds exhibited moderate to good 
antibacterial and antifungal activities. Especially the 
compounds 3j bearing 4-fluorophenyl piperazine 
moiety, 3h substituted with 4-nitrophenyl piperazine 
moiety, 3f having 1,3-dimethyl-2,6-dioxo-1,2,3,6-
tetrahydropyrimidin-4-yl moiety, 3i bearing 4-
chlorophenyl piperazine moiety, 3aincorporated with 
indole moiety; exhibited good activity against both 
Gram-positive and Gram-negative bacteria. The 
compounds 3g bearing propanoate moiety, 3j bearing 
4-fluorophenyl piperazine moiety, 3b incorporated 
with pentanoate moietyexhibited good activity against 
fungi when compared with the standard fungicide, 
Nystatin. All the remaining compounds showed 
moderate activity against both bacteria and fungi. 
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